Isis, Alnylam: More Serious Dating, But Still No Marriage
This article was originally published in The Pink Sheet Daily
Executive Summary
Latest collaboration involves the next step in RNAi research: single-stranded inhibitors against multiple disease targets.
You may also be interested in...
Deals Of The Week: Alnylam/Isis, Sanofi/Oxford & Bayer/Ardea
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Deals Of The Week: Alnylam/Isis, Sanofi/Oxford & Bayer/Ardea
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Sonus, OncoGenex Merge Into Specialty Oncology Company
Combined company will have three drugs in clinical development, including lead candidate OGX-011 in Phase II for prostate cancer.